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Abstract
Knowledge of carbapenem-resistant Klebsiella pneumoniae (CR-KP) colonization is important to prevent nosocomial spread but also to start
prompt adequate antibiotic therapy in patients with suspicion of infection. However, few studies have examined the incidence and risk
factors for CR-KP bloodstream infection (BSI) among rectal carriers. To identify risk factors for CR-KP BSI among carriers, we performed a
multicentre prospective matched case–control study of all adult CR-KP rectal carriers hospitalized in five tertiary teaching hospitals in Italy
over a 2-year period. Carriers who developed CR-KP BSI were compared with those who did not develop subsequent BSI. Overall, 143
CR-KP BSIs were compared with 572 controls without a documented infection during their hospitalization. Multivariate analysis revealed
that admission to the Intensive Care Unit (ICU) (OR, 1.65; 95% CI, 1.05–2.59; p 0.03), abdominal invasive procedure (OR, 1.87; 95% CI,
1.16–3.04; p 0.01), chemotherapy/radiation therapy (OR, 3.07; 95% CI, 1.78–5.29; p <0.0001), and number of additional colonization sites
(OR, 3.37 per site; 95% CI, 2.56–4.43; p <0.0001) were independent risk factors for CR-KP BSI development among CR-KP rectal carriers.
A CR-KP BSI risk score ranging from 0 to 28 was developed based on these four independent variables. At a cut-off of ≥2 the model
exhibited a sensitivity, specificity, positive predictive value and negative predictive value of 93%, 42%, 29% and 93%, respectively.
Colonization at multiple sites with CR-KP was the strongest predictor of BSI development in our large cohort of CR-KP rectal carriers.
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Introduction
Bloodstream infection (BSI) with carbapenem-resistant Klebsi-
ella pneumoniae (CR-KP) is associated with high morbidity and
mortality [1]. In-hospital mortality of patients with CR-KP BSI
is higher than that of patients with other types of CR-KP
infection [2,3]. Timely control of the source and appropriate
antibiotic treatment have been associated with better survival
[4–7].
CR-KP infection is usually preceded by colonization [8,9].
However, the incidence rate and risk factors for CR-KP BSI
among carriers is poorly understood. To date, only two
studies have analysed the risk factors for CR-KP infection
among rectal carriers. In such studies, patients with several
types of conditions were considered to have CR-KP infection,
from those with positive clinical samples without signs or
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symptoms of infection, to patients with urinary tract infection,
ventilator-associated pneumonia, surgical site infection, oste-
omyelitis and finally BSI [10,11]. Thus we believe that a study
focusing only on risk factors for CR-KP BSI among carriers
may provide physicians with useful information for managing
the most definitively-diagnosed severe manifestation of CR-KP
infection.
With the aim of developing a risk assessment for CR-KP BSI
among CR-KP carriers, we performed a multicentre prospec-
tive case–control study at five large tertiary-care teaching
hospitals in Italy over a 2-year study period.
Material and Methods
Study design and population
We performed a multicentre, prospective observational
case–control study of all adult (≥18 years) patients with a
CR-KP positive rectal swab, hospitalized from 1 January
2012 to 31 December 2013, to identify risk factors for
CR-KP BSI.
Cases consisted of patients with at least one episode of
CR-KP BSI and a positive rectal swab screening within 90 days
before drawing the positive blood cultures (BCs). Each case
patient was included only once at the time of the first CR-KP
isolation from BCs (index culture), even if more than one
CR-KP BSI was reported. The control group consisted of the
rectal carriers who did not develop subsequent CR-KP BSI or
other relevant infections (pneumonia, intra-abdominal infec-
tion or urinary tract infection). Matching was performed at a
ratio of 1:4 according to the time of the primary positive
CR-KP rectal swab (within the same month) and the time at
risk of having a subsequent infection (i.e. controls had to have
the same days of CR-KP carriage and follow-up time as their
matched cases prior to CR-KP BSI onset).
Setting
The study was carried out in five large tertiary-care teaching
hospitals in Italy with a cumulative admission rate of about
200 000 patients per year.
Rectal swabs were routinely performed at each study site
for all hospitalized patients with at least one of the following
criteria: (i) transfer from another hospital or long-term care
facility; (ii) sharing a room with a newly diagnosed CR-KP
infection or colonization patient; and (iii) admission to a
high-risk unit, including the intensive care unit (ICU), solid
organ transplant (SOT) unit and haematology departments.
The surveillance of other sites beside stools was not
systematically performed either in the ICU or in other
settings.
Data
Data were collected prospectively in a standardized case
report form. Underlying diseases were recorded according
to the Charlson’s score [12]. The risk factor variables were
considered from the time of diagnosis of colonization to BSI
onset (cases) or hospital discharge (controls). Invasive
hepatobiliary procedures included hepatic surgery, liver
transplantation, endoscopic retrograde cholangiopancreatog-
raphy, percutaneous biliary drainage and implant of biliary
stent; invasive abdominal procedures included open abdom-
inal surgery, endoscopic abdominal surgery and percutane-
ous drainage; other invasive procedures not mentioned
above were also recorded. Corticosteroid therapy was
defined by 16 mg prednisone-equivalent per day for
>15 days; neutropenia was defined as <500 neutrophil cells
per microlitre of blood for ≥7 days; chemotherapy and/or
radiation therapy were defined as receipt of cytotoxic
antineoplastic drugs or ionizing radiation for cancer cure or
palliation. Patients were followed until hospital discharge or
in-hospital mortality.
Definitions
Rectal carriers were defined as patients with CR-KP isolation
from the rectal swab in the absence of symptoms and signs of
invasive infection. In addition, every other sample positive for
CR-KP other than blood cultures, including urine samples,
respiratory samples, surgical site cultures and other skin
cultures, obtained from patients without clinical signs of
infection and who had not received a specific antibiotic
treatment, were considered as colonization apart from that
occurring in stools. CR-KP BSI was defined as a BSI
documented by blood culture positivity (at least one specimen)
for a CR-KP strain and clinical signs of the systemic inflam-
matory response syndrome [7]. BSI onset was considered as
the date of the index BC collection (i.e. the first BC that
yielded the study isolate).
Microbiological study
Rectal swabs were inoculated on a chromogenic agar plate
(Oxoid Brilliance CRE; Thermo Fisher Scientific, Cambridge
UK) containing a carbapenem antibiotic as selective agent.
Blood cultures were incubated using the BacTAlert auto-
mated system (bioMerieux, Marcy l’Etoile, France). The Vitek
2 automated system (bioMerieux) was used for isolate
identification and carbapenem resistance testing. Minimum
inhibitory concentrations (MICs) were classified according to
Clinical and Laboratory Standards Institute (CLSI) break-
points [13]. Bla genes were identified by polymerase chain
reaction (PCR) and sequencing according to standard
procedures [14].
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Statistical analysis
Categorical variables are expressed as absolute numbers and
their relative frequencies. Continuous variables are expressed
as mean  SD if normally distributed, or as median and
interquartile range (IQR) if non-normally distributed. Discrete
variables for the matched case–control pairs were compared
by McNemar’s test; for continuous variables we used the
Wilcoxon test. All the variables associated with CR-KP BSI in
the bivariate analysis (p <0.05) were included in a backward,
conditional stepwise multivariate logistic regression model.
The number of colonization sites was analysed as a continuous
variable to maximize predictive information, as recommended
by Royston et al. [15]. Overall goodness of fit was analysed by
Akiake’s Information Criteria (AIC) and Nagelkerke’s
R-square. Calibration of the model was assessed by comparing
predicted vs. actual probability of BSI. Discrimination of the
model was assessed by receiver-operator curve (ROC)
characteristics.
To develop the risk score, variables that maintained
statistical significance in the multivariate regression model
were assigned a point value corresponding to the b-coefficient
divided by the lowest b-coefficient identified in the regression
model, and the resulting quotient was multiplied by two and
rounded to the nearest whole number. Summation of the
points generated by the calculated risk factors resulted in a
quantitative score that was assigned to each patient in the
database.
The discrimination of risk score and development of BSI in
CR-colonized patients was then analysed by ROCs and an
optimal breakpoint was assigned using the Youden’s J statistic.
Time to development of BSI was estimated at different risk
score thresholds using Kaplan–Meier analysis. All statistical
tests were two-sided with a significance levels of p <0.05. The
analyses were performed using Stata 13 (College Station,
Texas, USA) and MedCalc version 13.0 (MedCalc Software
bvba, Ostend, Belgium).
Results
During the study period, we identified 1813 CR-KP rectal
carriers. Of them, 143 (7.8%) developed a CR-KP BSI after
colonization diagnosis, within a median of 19 days after the
first positive rectal swab (IQR 6–28 days). Cases were
compared with 572 control rectal carriers without a docu-
mented infection during their hospitalization. Most (n = 137,
95.8%) BSI isolates harboured blaKPC genes. In a random
sample including one-third of all isolates from rectal swabs, the
same percentage of strains were found to harbour blaKPC
genes.
In Table 1 we show the results of the bivariate analysis of
the comparison between CR-KP rectal carriers with BSI and
those without BSI. Variables associated with CR-KP BSI
development included: admission to the ICU; underlying
haematological disease; number of colonized sites besides
the stool; need for invasive procedures or devices, including
CVC, MV, PN, hepatobiliary and abdominal invasive proce-
dures; chemotherapy or radiation therapy; neutropenia; and
exposure to aminoglycosides and carbapenems. Controls had
a higher median age and Charlson’s comorbidity index, and
were more frequently admitted to a medical ward and
exposed to beta-lactam/beta-lactamase inhibitor antibiotics.
Multivariate analysis for matched data showed that admis-
sion to the ICU (OR ,1.65; 95% CI, 1.05–2.59; p 0.03), an
invasive abdominal procedure (OR, 1.88; 95% CI, 1.16–3.04;
p 0.011), chemotherapy/radiation therapy (OR, 3.07; 95% CI,
1.78–5.29; p <0.0001) and colonization at additional sites
besides the stool (OR, 3.37 per each additional site; 95% CI,
2.56–4.43; p <0.0001) were independent risk factors for
CR-KP BSI development among CR-KP rectal carriers. Over-
all, the model displayed acceptable goodness of fit, correctly
predicting CR-KP BSI status in 84.0% of patients with a
pseudo-R square (Nagelkere) of 0.32 (p <0.0001).
Assignment of points on the basis of the odds ratios for
these four independent variables generated an individual risk
score for each patient ranging from 0 to 28 (mean 3.9, 95% CI
3.5–4.2) (Table 2). Risk scores were significantly higher among
colonized patients who developed BSI within 90 days com-
pared with patients who did not develop BSI (mean 8.4 vs. 2.7;
p <0.0001). The rate of CR-KP BSI predicted by the risk score
and that observed were well calibrated (Fig. 1a). ROC curve
analysis suggested that the risk score could acceptably
discriminate low risk vs. higher risk patients with an area
under the curve of 0.80 (0.77–0.83), p <0.0001 (Fig. 1b). For a
risk score of ≥2, the sensitivity, specificity, positive predictive
value and negative predictive value were 93.0% (87.5–96.6),
42.0% (37.9–46.1), 28.6% (24.5–32.9) and 96% (92.8–98.1),
respectively. The positive and negative likelihood ratios (LRs)
associated with a ≥2 score cut-off were 1.60 and 0.17,
respectively. Considering the pre-test incidence of 7.8% of BSI
in the population of colonized patients screened for this study
and the negative LR of 0.17, patients with a risk score of <2
would be predicted to have a 1.5% probability (95% CI, 1–3) of
developing BSI. In the matched cohort used to develop the risk
score with a higher BSI prevalence (20%), a score of <2
identified patients with a 4% probability (95% CI, 3–6%) of
developing a BSI.
Kaplan–Meier curves were constructed to estimate the
median time to BSI development for patients at five different
risk score thresholds (0, 2, 3–10, 11–14 and ≥15) (Fig. 2). The
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30-day CR-KP BSI risk rates were 2%, 7%, 22%, 38% and 63%
for carriers with a score of 0, 2, 3–10, 11–14 and ≥15,
respectively. The 90-day CR-KP BSI risk rates were 4%, 12%,
26%, 61% and 100% for carriers with a score of 0 (n = 250), 2
(n = 142), 3–10 (n = 258), 11–14 (n = 38) and ≥15 (n = 27),
respectively (Fig. 2).
Discussion
In this prospective, multicentre observational case–control
study, we found that the 7.8% of CR-KP rectal carriers
developed BSI with CR-KP. Colonization at multiple sites was
the strongest predictor of BSI development in our cohort.
With the worldwide dissemination of CR-KP, many hospi-
tals have introduced infection control programmes to limit
Cases
(CR-KP rectal
carriers who
developed BSI)
N = 143 (%)
Controls
(CR-KP rectal
carriers who did
not develop BSI)
N = 572 (%) P
Demographic data
Age (years), median (IQR)a 65 (52–75) 70 (58–81) <0.001
Male sex 84 (58.7) 307 (53.7) 0.28
Hospital ward
Medicinea 50 (35.0) 262 (45.8) 0.019
Surgery 31 (21.7) 142 (24.8) 0.43
ICUa 61 (42.7) 168 (29.4) 0.002
Comorbid condition
Charlson’s score, median (IQR)a 2 (2–4) 4 (2.5–4) <0.001
Haematological malignancya 28 (19.6) 44 (7.7) <0.001
Solid tumour 26 (18.2) 136 (23.8) 0.15
HIV infection 2 (1.4) 7 (1.2) 0.87
Solid organ transplantation 13 (9.1) 56 (9.8) 0.80
Other underlying conditions
Prior hospitalization within the last 3 months 85 (59.4) 368 (64.4) 0.27
Transfer from another healthcare facility 12 (8.4) 61 (10.7) 0.42
Number of colonized sites besides stool
0 49 (34.3) 424 (74.1) <0.001
1 41 (28.7) 127 (22.2) 0.10
2 26 (18.2) 21 (3.7) <0.001
3 21 (14.7) 0 <0.001
≥4 6 (4.2) 0 <0.001
Median (IQR)a 1 (0–2) 0 (0–1) <0.001
At least one site colonized besides stool 94 (65.7) 148 (25.8) <0.001
At least two sites colonized besides stool 53 (37.1) 21 (3.7) <0.001
Invasive procedures and devicesb
ICU admissiona 27 (18.9) 56 (9.8) 0.002
CVCa 91 (63.6) 297 (51.9) 0.01
Urinary catheter 73 (51.0) 325 (56.8) 0.21
Mechanical ventilationa 59 (41.3) 161 (28.2) 0.002
Parenteral nutritiona 51 (35.7) 105 (18.4) <0.001
RRT 11 (7.7) 34 (5.9) 0.44
Hepatobiliary invasive proceduresa 12 (8.4) 12 (2.1) <0.001
Abdominal invasive proceduresa 63 (44.1) 94 (16.4) <0.001
Other invasive procedures 7 (4.9) 24 (4.2) 0.71
Immunosuppressive therapyb
Corticosteroid therapy 35 (24.5) 114 (19.9) 0.23
Chemotherapy/radiotherapya 33 (23.1) 67 (11.7) <0.001
Neutropeniaa 21 (14.7) 26 (4.5) <0.001
Antibiotic exposureb
Any antibiotic 124 (86.7) 486 (85.0) 0.60
By classes
Aminoglycosidesa 22 (15.4) 45 (7.9) 0.006
b-lactam-b-lactamase inhibitorsa 71 (49.6) 341 (59.6) 0.03
Fluoroquinolones 54 (37.8) 178 (31.2) 0.13
Oxyimino cephalosporins 12 (8.4) 38 (6.6) 0.46
Carbapenemsa 52 (36.4) 137 (23.9) 0.003
Glycopeptides 28 (19.6) 87 (15.2) 0.20
Outcome
Days of hospital stay, median (IQR) 47 (27–77) 34 (20–58) <0.001
In-hospital mortality 75 (52.4) 120 (20.9) <0.001
IQR, interquartile range; ICU, intensive care unit; CVC, central venous catheter; RRT, renal replacement therapy.
aThese variables were included in the multivariate analysis.
bThese variables were considered from the CR-KP rectal carriage diagnosis to the CR-KP BSI onset for cases, or to
hospital discharge for controls.
TABLE 1. Bivariate analysis of risk
factors associated with CR-KP BSI
among CR-KP rectal carriers
TABLE 2. Logistic regression analysis of risk factors for
CR-KP BSI development in rectal carriers
OR (95% CI) P-value
Risk score
point
Admission to ICU 1.65 (1.05–2.59) 0.03 2
Invasive abdominal procedures 1.87 (1.16–3.04) 0.01 3
Chemotherapy/radiation therapy 3.07 (1.78–5.29) <0.0001 4
Colonization at site besides stool
(risk per each additional site)
3.37 (2.56–4.43) <0.0001 5 per site
ICU, intensive care unit; OR, odds ratio.
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CR-KP spread, infection rate and attributable morbidity and
mortality [16]. Active surveillance is strongly recommended
for timely detection of carriers, separation of carriers from
non-carriers, and activation of contact precautions. Informa-
tion concerning carrier and/or colonization status may be also
useful to guide antibiotic treatment upon suspicion of infection.
However, data concerning the incidence of and risk factors for
invasive infection in CR-KP carriers are limited. Of the two
studies published to date, the first analysed 464 patients
hospitalized at a large teaching hospital in Israel, showing that
9% of carriers developed infection; the independent risk
factors for infection were previous invasive procedures,
diabetes mellitus, solid tumour, tracheostomy, urinary cathe-
terization and prior use of anti-pseudomonas penicillins [10].
In the second study, 44 (8.8%) of 502 CR-KP carriers
developed subsequent positive clinical cultures with CR-KP.
Of them, 38 were classified as having a CR-KP infection. Risk
factors for subsequent positive clinical samples were admission
to the intensive care unit, having a central venous catheter,
receipt of antibiotics and diabetes mellitus [11].
In our large cohort of CR-KP rectal carriers, the rate of
CR-BSI was 7.8%, not so low that upon suspicion of infection
the need for CR-KP coverage would be considered to be
negligible, nor so high that antibiotic coverage should be
considered to be always necessary in stable carriers with
symptoms of infection. Thus, a predictive score of BSI to guide
therapeutic decisions in CR-KP carriers may be helpful for
avoiding unnecessary potential toxic antimicrobial therapy in
low-risk patients, and for starting adequate treatment
promptly in those at high risk. The relatively high negative
predictive value of our model suggests that CR-KP rectal
carriers with lower risk scores (<2) and without signs or
symptoms of severe sepsis-septic shock could potentially be
managed more conservatively initially if BSI is suspected,
without immediate administration of potentially toxic,
broad-spectrum antibiotics.
Our study has some limitations. First, the dates of the
beginning and end of risk factors were not available for all
patients, therefore we could not analyse the temporal
relationship between colonization diagnosis, risk factors and
infection. However, the interval between detection of the
carrier status and BSI development was <1 month for almost
all patients. Hence, we can conclude that our score is valid for
all patients with a time at risk of 1 month. Another issue is that
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the detection of carrier status may not coincide with the time
of colonization acquisition, and some patients with negative
rectal swab may have acquired colonization at later time
periods. However, our strategy of performing active surveil-
lance only in some high-risk circumstances is the standard of
care actually recommended for CR-KP nosocomial spread
[16]. We did not match for the setting in which the
colonization status was detected. However, the surveillance
strategy was the same in each study site for all hospitalized
patients. The rates of BSI among haematological, SOT, ICU and
medicine carriers were 38.9%, 18.8%, 18.5% and 16%, respec-
tively. Studies addressing the risk factors for BSI/invasive
infection in each setting of the carriers may be helpful in
designing tailored preventive or treatment strategies. Further-
more, surveillance cultures other than rectal swabs were not
routinely performed but requested by attending physicians on
a clinical basis. This may have generated a bias of our results,
overestimating the meaning of multisite colonization. Studies in
which multisite colonization is systematically checked in
high-risk patients (i.e. haematological patients, SOT recipients
and patients admitted in ICU) should be carried out to confirm
the predictive role for BSI in multisite colonization. Finally, our
score was not prospectively validated. However, it was
obtained from a very large multicentre cohort representative
of Italian CRE carriers and infected patients. An external
validation of patients hospitalized in large tertiary hospitals in
countries suffering the same CRE endemicity as in our country,
may be useful to assess the reproducibility of our results.
To conclude, in our large cohort of CR-KP carriers, ICU
admission, invasive abdominal procedures, chemotherapy/radi-
ation therapy and colonization at other sites besides stools were
independent risk factors for BSI. A predictive model with these
variables may be useful to identify patients at low risk of CR-KP
BSI and avoid overuse of broad-spectrum therapy. However,
further studies are needed to validate our results.
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